Xenetic Biosciences, Inc.
XBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.72
KIRA · Stoqly’s AI analyst, in plain words
- Xenetic Biosciences, Inc. had $3.0M of revenue in fiscal 2025, up 19.0% on the year before. Over five years, revenue changed +46.8% a year on average.
- Its operating margin was −95.2%, up 72.9 pts: of every 100 in sales, about −95 is left after running the business.
- Xenetic Biosciences, Inc. lost $2.7M in fiscal 2025.
Market cap
$3.9M
P/E
—
Revenue
$3.0M
Net income
−$2.7M
Free cash flow
—
Operating margin
−95.2%
Xenetic Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+19.0%
Yes. Sales grew 19.0% last year.
Does it make a profit?
−90.1%
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xenetic Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Xenetic Biosciences, Inc.
- CIK
- 0001534525
Xenetic Biosciences, Inc. · XBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2M | $1.7M | $2.5M | $2.5M | $3.0M |
| Revenue growth | 165.7% | 47.1% | 48.8% | −1.6% | 19.0% |
| Net interest income | $0.1M | $0.2M | $0.4M | $0.2M | $0.1M |
| Operating margin | −495.1% | −393.6% | −177.8% | −168.2% | −95.2% |
| Net income | −$5.6M | −$6.6M | −$4.1M | −$4.0M | −$2.7M |
| Net margin | −486.4% | −383.9% | −162.8% | −158.4% | −90.1% |
| Diluted EPS | −$0.55 | −$4.61 | −$2.71 | −$2.57 | −$1.58 |
| Cash | |||||
| Cash from operations | −$4.7M | −$4.6M | −$4.1M | −$2.8M | −$2.3M |
| Share count change | 60.8% | −86.2% | 7.4% | 0.9% | 10.4% |
| Debt and strength | |||||
| Cash and short-term investments | $18.2M | $13.1M | $9.0M | $6.2M | $7.9M |
| Shareholders' equity | $18.4M | $13.6M | $9.8M | $6.0M | $7.4M |
| Current ratio | 13.2x | 12.7x | 11.8x | 7.4x | 8.3x |
| Returns and quality | |||||
| Return on equity | −36.9% | −40.9% | −35.3% | −50.1% | −40.0% |
| Return on tangible equity | −30.7% | −48.0% | −42.2% | −65.9% | −36.2% |
| Piotroski F-score | 3 | 3 | 3 | 2 | 3 |
| Altman Z'' | −12.7 | −26.0 | −44.1 | −84.8 | −66.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xenetic Biosciences, Inc. · XBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.72 a share, the company is worth $3.9M.
Source: SEC EDGAR XBRL filings (CIK 0001534525). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.